Roquette announces its 2024 full year results

Driven by its Pharmaceutical Activities, Roquette's 2024 Results Demonstrate the Resilience of its Integrated Business Model

• Commercial performance in line with a market which remains below historical levels. 2024 turnover of €4,495 million (-10% vs. 2023).
• Rigorous cost management has allowed the Group to maintain margin levels (11.8% in 2024 compared with 12.2% in 2023), with a consolidated EBITDA of €529 million (-13% vs. 2023).
• A significant improvement in Free Cash-Flow, at €275 million, mainly driven by Roquette’s financial discipline and easing inflationary pressure on working capital requirement.
• The acquisition of IFF Pharma Solutions, expected to be completed in Q2 2025, will strengthen the Pharma Solutions activities.
• Successful inaugural dual tranche bond issue raising €1.2 billion to finance part of the IFF Pharma Solutions acquisition.

Lille – March 21st, 2025 – Roquette announces today its 2024 full year results following the approval of its financial statements by the Board of Directors on March 20th, 2025.

On this occasion, Pierre Courduroux, Roquette's CEO, commented: “Roquette delivered a resilient financial performance in 2024. Our Pharma Solutions business continued its development, with a strong growth that confirms our strategy to reinforce our leadership in this market. Despite a challenging environment, our Core Ingredients activities are in line with a market which remains below historical levels.”

2024 was marked by a strong Free Cash-Flow, supported by Roquette’s operational excellence, its financial discipline, and the easing of inflationary pressures. The reduction in net debt places the group in a strong position to execute its ambitious investment strategy. “The ongoing acquisition of IFF Pharma Solutions marks a strategic milestone for the Group. It will enable us to better balance our portfolio between health and nutrition, reducing our exposure to commodity price fluctuations while strengthening our global presence in high-value markets, and particularly with a larger industrial footprint in the USA. In addition, the success of our first dual tranche bond issue demonstrates investor confidence and marks the beginning of a new phase of sustainable value creation for all our stakeholders,” emphasized Pierre Courduroux.

Despite an uncertain economic environment, Roquette enters 2025 with confidence in its strategy, supported by the resilience of its integrated model, the diversity of its portfolio, and its global presence. Rigorous cost management and the continued growth of the Pharma Solutions business reinforce this momentum. Like other industries, visibility for the year remains limited, and Roquette stays fully focused on its strategic priorities. “In 2025, our priority will be to successfully integrate IFF Pharma Solutions, while maintaining the performance of our activities. We will also continue to strengthen our competitiveness and focus on deleveraging. The acquisition of IFF Pharma Solutions, scheduled for the second quarter of 2025, is unique due to the complementary nature of our portfolios and our industrial footprints. It will significantly strengthen Roquette's position as a key partner for global pharmaceutical companies, with a broad range of drug delivery solutions featuring diverse excipient technologies. This transformative step will pave the way for sustainable growth and long-term success for Roquette,” concluded Pierre Courduroux.

Please download the full press release below.

Press contacts

• Brunswick: Antoine Parison - +33 (0) 7 88 72 28 95 - aparison@brunswickgroup.com
• Roquette Corporate Communications: Susannah Duquesne - Susannah.duquesne@roquette.com
• Roquette Financial Communications: Eloïse de la Chaux - eloise.de-la-chaux@roquette.com